Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Vol. 225. Issue 2.
Pages 57-116 (February 2025)
Cite
Cite
Share
Download PDF
More article options
Visits
1880
Vol. 225. Issue 2.
Pages 57-116 (February 2025)
Original article

Which one is a better predictor of prognosis in COVID-19: analytical biomarkers or PaO2/FiO2?

¿Cuál es mejor predictor del pronóstico en COVID-19: biomarcadores analíticos o PaO2/FiO2?
Visits
1880
M. Rubio-Rivasa,
Corresponding author
mrubio@bellvitgehospital.cat

Corresponding author.
, J.M. Mora-Lujánb, A. Montero Sáeza, M.D. Martín-Escalantec, V. Giner Galvañd, G. Maestro de la Callee, M.L. Taboada Martínezf, A. Muiño Míguezg, C. Lumbreras-Bermejoe, J.-M. Antón-Santosh, on behalf of the SEMI-COVID-19 Network 1
a Department of Internal Medicine, Bellvitge University Hospital, Barcelona, Spain
b Department of Internal Medicine, Parc Sanitari Hospital del Mar, Barcelona, Spain
c Department of Internal Medicine, Costa del Sol Hospital, Marbella, Málaga, Spain
d Department of Internal Medicine, San Juan de Alicante University Hospital, Alicante, Spain
e Department of Internal Medicine, 12 de Octubre University Hospital, Madrid, Spain
f Department of Internal Medicine, Cabueñes Hospital, Gijón, Asturias, Spain
g Department of Internal Medicine, Gregorio Marañón University Hospital, Madrid, Spain
h Department of Internal Medicine, Infanta Cristina University Hospital, Parla, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Background

The study aimed to describe patient characteristics and outcomes by PaO2/FiO2 (PAFI) and degree of inflammation.

Methods

Retrospective cohort study with data on patients collected from March 1st, 2020 to March 1st, 2023, from the Spanish SEMI-COVID-19 Registry. Non-nosocomial patients with data on PAFI (<100 vs. 100−200 vs. 200−300 vs. >300) who received corticosteroids (CS) for COVID-19 in the first 48&#¿;h of admission were included in the study. 5314 patients met the inclusion criteria for the present study. The primary outcome was in-hospital mortality.

Results

Higher in-hospital mortality was found in the groups with PAFI&#¿;<&#¿;100 (51.5% vs. 41.2% vs. 25.8% vs. 12.3%, P&#¿;<&#¿;.001). They also required more NIMV, IMV, and ICU admission, and had longer hospital stays. Those patients with PAFI&#¿;>&#¿;300 and 4–5 high-risk criteria presented higher mortality than the patients with PAFI 200−300 and only 1−2 criteria of analytical inflammation. Risk factors associated with higher in-hospital mortality were age [OR&#¿;=&#¿;1.06 (1.05−1.06)], moderate [OR&#¿;=&#¿;1.87 (1.49−2.33)] and severe [OR&#¿;=&#¿;2.64 (1.96−3.55)] degree of dependency, dyslipidemia [OR&#¿;=&#¿;1.20 (1.03−1.39)], higher Charlson index [OR&#¿;=&#¿;1.19 (1.14−1.24)], tachypnea on admission [2.23 (1.91−2.61)], the higher number of high-risk criteria on admission, and lower PAFI on admission. Female gender [OR&#¿;=&#¿;0.77 (0.65−0.90)] and the use of RDSV [OR&#¿;=&#¿;0.72 (0.56−0.93)] were found to be protective factors.

Conclusions

The lower the PAFI and the higher the degree of inflammation in COVID-19, the higher the in-hospital mortality. Inflammatory escalation precedes respiratory deterioration and should serve as an early predictor of severity to deciding the use of anti-inflammatory/immunosuppressive therapy.

Keywords:
COVID-19
PaO2/FiO2
Inflammation
Prognosis
Mortality
Abbreviations:
BMI
COPD
CRP
CS
HFNC
ICU
IMV
IQR
LDH
LMWH
NIMV
OSAS
PAFI
PCR
RDSV
SD
SEMI
TCZ
Resumen
Antecedentes

El estudio tenía como objetivo describir las características y los resultados de los pacientes según la PaO2/FiO2 (PAFI) y el grado de inflamación.

Métodos

Estudio de cohortes retrospectivo con datos de pacientes recogidos desde el 1 de marzo de 2020 hasta el 1 de marzo de 2023, del Registro Español SEMI-COVID-19. Se incluyeron en el estudio pacientes no nosocomiales con datos de PAFI (<100 vs 100−200 vs 200−300 vs >300) que recibieron corticoides (CS) por COVID-19 en las primeras 48&#¿;h de ingreso. 5.314 pacientes cumplieron los criterios de inclusión para el presente estudio. El resultado primario fue la mortalidad intrahospitalaria.

Resultados

Se encontró mayor mortalidad intrahospitalaria en los grupos con PAFI&#¿;<&#¿;100 (51,5% vs 41,2% vs 25,8% vs 12,3%, P&#¿;<&#¿;,001). También requirieron más VMNI, VMI e ingreso en UCI, y tuvieron estancias hospitalarias más prolongadas. Los pacientes con PAFI&#¿;>&#¿;300 y 4–5 criterios de alto riesgo presentaron mayor mortalidad que los pacientes con PAFI 200−300 y sólo 1−2 criterios de inflamación analítica. Los factores de riesgo asociados a una mayor mortalidad intrahospitalaria fueron la edad [OR&#¿;=&#¿;1,06 (1,05–1,06)], el grado de dependencia moderado [OR&#¿;=&#¿;1,87 (1,49–2,33)] y grave [OR&#¿;=&#¿;2,64 (1,96–3,55)], la dislipidemia [OR&#¿;=&#¿;1, 20 (1,03–1,39)], mayor índice de Charlson [OR&#¿;=&#¿;1,19 (1,14–1,24)], taquipnea al ingreso [2,23 (1,91–2,61)], mayor número de criterios de alto riesgo al ingreso y menor PAFI al ingreso. El sexo femenino [OR&#¿;=&#¿;0,77 (0,65–0,90)] y el uso de RDSV [OR&#¿;=&#¿;0,72 (0,56–0,93)] resultaron ser factores protectores.

Conclusiones

A menor PAFI y mayor grado de inflamación en COVID-19, mayor mortalidad intrahospitalaria. La escalada inflamatoria precede al deterioro respiratorio y debería servir como predictor precoz de gravedad para decidir el uso de terapia antiinflamatoria/inmunosupresora.

Palabras clave:
COVID-19
PaO2/FiO2
Inflamación
Pronóstico
Mortalidad

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.

Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":

>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Revista Clínica Española (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
References
[1]
F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet., 395 (2020), pp. 1054-1062
[2]
R. Díaz-Simón, A. Lalueza, J. Lora-Tamayo, M. Rubio-Rivas, C.L. Mendo, M.L.T. Martínez, et al.
Clinical characteristics and risk factors of respiratory failure in a cohort of young patients requiring hospital admission with SARS-CoV2 infection in Spain: results of the multicenter SEMI-COVID-19 registry.
J Gen Intern Med., 36 (2021), pp. 3080-3087
[3]
A.B. Li, B. Yang, Y. Li, R. Huynh, S. Shim, K. Lo, et al.
A network meta-analysis of association between cardiometabolic risk factors and COVID-19 outcome severity.
J Diabetes., 15 (2023), pp. 968-977
[4]
A. Mehri, S. Sotoodeh Ghorbani, K. Farhadi-Babadi, E. Rahimi, Z. Barati, N. Taherpour, et al.
Risk factors associated with severity and death from COVID-19 in Iran: a systematic review and meta-analysis study.
J Intensive Care Med., 38 (2023), pp. 825-837
[5]
R. Kowsar, A.M. Rahimi, M. Sroka, A. Mansouri, K. Sadeghi, E. Bonakdar, et al.
Risk of mortality in COVID-19 patients: a meta- and network analysis.
[6]
C.I. Vardavas, A.G. Mathioudakis, K. Nikitara, K. Stamatelopoulos, G. Georgiopoulos, R. Phalkey, et al.
Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe.
Eur Respir Rev., 31 (2022),
[7]
Z.G. Dessie, T. Zewotir.
Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.
BMC Infect Dis., 21 (2021), pp. 855
[8]
J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, et al.
Remdesivir for the treatment of Covid-19 - final report.
N Engl J Med., 383 (2020), pp. 1813-1826
[9]
P. Horby, W.S. Lim, J.R. Emberson, M. Mafham, J.L. Bell, L. Linsell, RECOVERY Collaborative Group, et al.
Dexamethasone in hospitalized patients with Covid-19.
N Engl J Med., 384 (2021), pp. 693-704
[10]
J.M. Mora-Luján, M. Tuells, A. Montero, F. Formiga, N.A. Homs, J. Albá-Albalate, et al.
High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis.
J Clin Med., 10 (2021), pp. 4465
[11]
C. Lavilla Olleros, C. Ausín García, A.D. Bendala Estrada, A. Muñoz, P.E. Wikman Jogersen, A. Fernández Cruz, et al.
Use of glucocorticoids megadoses in SARS-CoV-2 infection in a Spanish registry: SEMI-COVID-19.
PLoS One., 17 (2022),
[12]
M. Rubio-Rivas, J.M. Mora-Luján, A. Montero, J.A. Aguilar García, M. Méndez Bailón, A. Fernández Cruz, et al.
The use of corticosteroids or tocilizumab in COVID-19 based on inflammatory markers.
J Gen Intern Med., 37 (2022), pp. 168-175
[13]
M. Rubio-Rivas, M. Ronda, A. Padulles, F. Mitjavila, A. Riera-Mestre, C. García-Forero, et al.
Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
Int J Infect Dis., 101 (2020), pp. 290-297
[14]
I.M. Tleyjeh, Z. Kashour, M. Riaz, L. Hassett, V.C. Veiga, T. Kashour.
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis-first update.
Clin Microbiol Infect., (2021),
[15]
M. Rubio-Rivas, C.G. Forero, J.M. Mora-Luján, A. Montero, F. Formiga, N.A. Homs, et al.
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.
Pharmacotherapy., 41 (2021), pp. 884-906
[16]
G. Pomponio, A. Ferrarini, M. Bonifazi, M. Moretti, A. Salvi, A. Giacometti, et al.
Tocilizumab in COVID-19 interstitial pneumonia.
[17]
F. Perrone, M.C. Piccirillo, P.A. Ascierto, C. Salvarani, R. Parrella, A.M. Marata, et al.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
J Transl Med., 18 (2020), pp. 405
[18]
A.C. Gordon, P.R. Mouncey, F. Al-Beidh, K.M. Rowan, A.D. Nichol, Y.M. Arabi, REMAP-CAP Investigators, et al.
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
N Engl J Med., (2021),
[19]
I.O. Rosas, N. Bräu, M. Waters, R.C. Go, B.D. Hunter, S. Bhagani, et al.
Tocilizumab in hospitalized patients with severe Covid-19 pneumonia.
N Engl J Med., (2021),
[20]
A.S. Soin, K. Kumar, N.S. Choudhary, P. Sharma, Y. Mehta, S. Kataria, et al.
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
Lancet Respir Med., (2021),
[21]
D. Wang, B. Fu, Z. Peng, D. Yang, M. Han, M. Li, et al.
Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
Front Med., (2021), pp. 1-9
[22]
RECOVERY Collaborative Group.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet., 397 (2021), pp. 1637-1645
[23]
G. Sinatti, S.J. Santini, G. Tarantino, G. Picchi, B. Cosimini, F. Ranfone, et al.
PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study.
Intern Emerg Med., 17 (2022), pp. 665-673
[24]
S. Sartini, L. Massobrio, O. Cutuli, P. Campodonico, C. Bernini, M. Sartini, et al.
Role of SatO2, PaO2/FiO2 ratio and PaO2 to predict adverse outcome in COVID-19: a retrospective, cohort study.
Int J Environ Res Public Health., 18 (2021), pp. 11534
[25]
A. Zinellu, A. De Vito, V. Scano, P. Paliogiannis, V. Fiore, G. Madeddu, et al.
The PaO2/FiO2 ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients.
J Infect Dev Ctries., 15 (2021), pp. 353-359
[26]
A. Russo, M. Pisaturo, I. De Luca, F. Schettino, P. Maggi, F.G. Numis, et al.
Lactate dehydrogenase and PaO2/FiO2 ratio at admission helps to predict CT score in patients with COVID-19: an observational study.
J Infect Public Health., 16 (2023), pp. 136-142
[27]
J.M. Casas-Rojo, J.M. Antón-Santos, J. Millán-Núñez-Cortés, C. Lumbreras-Bermejo, J.M. Ramos-Rincón, E. Roy-Vallejo, et al.
Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 registry.
Rev Clin Esp., 220 (2020), pp. 480-494
[28]
M. Rubio-Rivas, X. Corbella, F. Formiga, E. Menéndez Fernández, M.D. Martín Escalante, I. Baños Fernández, et al.
Risk categories in COVID-19 based on degrees of inflammation. Data on more than 17,000 patients from the Spanish SEMI-COVID-19 registry.
J Clin Med., (2021),
[29]
M. Rubio-Rivas, J.M. Mora-Luján, F. Formiga, C. Arévalo-Cañas, J.M. Lebrón Ramos, M.V. Villalba García, et al.
WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales.
[30]
S. Dhont, E. Derom, E. Van Braeckel, P. Depuydt, B.N. Lambrecht.
The pathophysiology of ‘happy’ hypoxemia in COVID-19.
Respir Res., 21 (2020), pp. 198
[31]
M. Rubio-Rivas, J.M. Mora-Luján, F. Formiga, M.Á. Corrales González, M.D.M. García Andreu, V. Moreno-Torres, et al.
Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry.
Intern Emerg Med., (2022), pp. 1-13
Idiomas
Revista Clínica Española (English Edition)
Article options
Tools
Supplemental materials